Celgene beats earnings estimate but misses on sales

27 April 2017
2019_biotech_test_vial_discovery_big

US biotech Celgene (Nasdaq: CELG) slipped by 0.4% in four hours of trading on Thursday to $124.70 after reporting its first quarter financials, reflecting a mixed bag of results.

Celgene reported net product sales of $2.95 billion for the quarter, an 18% increase from the same period in 2016, but short of the estimates of surveyed analysts which averaged $3.04 billion.

The company’s earnings for the quarter, meanwhile, beat estimates. Adjusted net income for the first quarter of 2017 increased by 28% to $1.36 million compared to $1.06 million in the previous year. Adjusted diluted earnings per share (EPS) were $1.68, ahead of the $1.64 predicted by analysts.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology